Cardiometabolic diseases impose a great burden for our health systems. Despite of recent prominent progresses in medicine and evidence-based therapies, structural and functional alterations of cardiometabolic system continues to culminate in the increased morbidity and mortality. For example, cardiovascular dysfunctions are manifested as progressive ventricular dilatation, deterioration of cardiac function, endothelial dysfunction and hypertension. Many classical drugs are in clinical usage to help maintain and restore cardiovascular and metabolic function yet cardiovascular mortality remains high. A better understanding of the genetic and epigenetic regulation of cardiometabolic function should help to identify new drug targets (such as SGLT-2) to address the high prevalence of cardiometabolic anomalies.
The goal of this Research Topic is to provide a concise but comprehensive review on some of the new drug targets in proteotoxicity and protein quality in cardiometabolic diseases as well as the clinical implications of targeting these aspects in cardiometabolic disease. This is a critically important area in understanding the progression of cardiometabolic diseases and the development of therapeutic strategies to improve cardiometabolic health. This issue should provide an important and easily accessible reference for scientists and clinicians to understand the scope of this topic. For basic scientists, this issue will provide a clinical context and for clinicians, the scientific underpinning of the role of molecular basis of new intervention for cardiovascular diseases. This Research Topic is aimed at identifying new therapeutic targets, drug developed and translational approaches targeting proteotoxicity in various cardiometabolic diseases, hoping to broaden the scope of clinical management of cardiometabolic diseases.
The subtopics to be covered in the Research Topic include, but not limited to:
1. Latest information on perturbations in protein quality control in cardiometabolic homeostasis in patients with cardiovascular and metabolic diseases.
2. Clinically relevant information on the effects of therapies for cardiometabolic diseases
3. Review of novel approaches to modulate energy metabolism, mitochondrial integrity and improve cardiovascular function in patients with cardiometabolic diseases.
Both original work and review articles are welcome.
Cardiometabolic diseases impose a great burden for our health systems. Despite of recent prominent progresses in medicine and evidence-based therapies, structural and functional alterations of cardiometabolic system continues to culminate in the increased morbidity and mortality. For example, cardiovascular dysfunctions are manifested as progressive ventricular dilatation, deterioration of cardiac function, endothelial dysfunction and hypertension. Many classical drugs are in clinical usage to help maintain and restore cardiovascular and metabolic function yet cardiovascular mortality remains high. A better understanding of the genetic and epigenetic regulation of cardiometabolic function should help to identify new drug targets (such as SGLT-2) to address the high prevalence of cardiometabolic anomalies.
The goal of this Research Topic is to provide a concise but comprehensive review on some of the new drug targets in proteotoxicity and protein quality in cardiometabolic diseases as well as the clinical implications of targeting these aspects in cardiometabolic disease. This is a critically important area in understanding the progression of cardiometabolic diseases and the development of therapeutic strategies to improve cardiometabolic health. This issue should provide an important and easily accessible reference for scientists and clinicians to understand the scope of this topic. For basic scientists, this issue will provide a clinical context and for clinicians, the scientific underpinning of the role of molecular basis of new intervention for cardiovascular diseases. This Research Topic is aimed at identifying new therapeutic targets, drug developed and translational approaches targeting proteotoxicity in various cardiometabolic diseases, hoping to broaden the scope of clinical management of cardiometabolic diseases.
The subtopics to be covered in the Research Topic include, but not limited to:
1. Latest information on perturbations in protein quality control in cardiometabolic homeostasis in patients with cardiovascular and metabolic diseases.
2. Clinically relevant information on the effects of therapies for cardiometabolic diseases
3. Review of novel approaches to modulate energy metabolism, mitochondrial integrity and improve cardiovascular function in patients with cardiometabolic diseases.
Both original work and review articles are welcome.
